MONTREAL -- (BUSINESS WIRE) -- Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced the appointment of Donald Notman as Senior Vice President and Chief Financial Officer. Mr. Notman brings over 20 years of investment banking and financial experience complemented by five years of start-up and venture capital experience.
“We are delighted to have Donald join us as we continue to build our Company; this is a critical time in the company’s growth and Donald’s extensive experience will significantly strengthen our executive management team,” said Richard Andrews, President and Chief Executive Officer of Thrasos. “I am confident that he will provide us with tremendous guidance as we continue to progress THR-184 through its phase 2 clinical program in acute kidney injury and prepare for our next program in diabetic nephropathy.”
During his nearly 20 year career in investment banking, Mr. Notman has completed aggregate financings in excess of $2.5 billion across more than 75 private and public development stage companies, primarily in the health care and technology industries. Previously, he was a Managing Director and Head of Private Capital Markets for seven years at Leerink Partners, a health care-only investment bank. Prior to that, he spent nearly a decade at Alex. Brown & Sons and its successor organization Deutsche Banc Alex. Brown, where his most recent position was Managing Director and Global Group Head of Equity Private Placements. Mr. Notman received a BA in Economics from Middlebury College and a MBA from the Tuck School of Business at Dartmouth College.
“I am very excited to be joining a leadership team so committed to bringing new solutions to kidney patients in need and am impressed with the potential of the company’s technology to treat and prevent the severe consequences of this disease,“ said Mr. Notman.
About Acute Kidney Injury (AKI)
AKI is the sudden loss of kidney function, and it affects more than 1.2 million people each year in the United States. It is particularly frequent in patients hospitalized for major surgery, including cardiac and/or vascular surgery, trauma, infection, cardiac disease or cancer. AKI can lead to a permanent reduction of kidney function and is also associated with an increased risk of death, extended hospitalization and significantly increased medical cost. There are currently no available therapies to prevent or treat AKI.
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company’s lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease. www.thrasos.com